Thelansis

 Calciphylaxis, or calcific uremic arteriolopathy (CUA), is a rare condition characterized by subcutaneous vascular calcification and cutaneous necrosis. It is frequently observed in individuals with renal failure. This condition is alternatively referred to as metastatic calcinosis cutis and necrotizing or calcifying panniculitis. The precise underlying mechanisms of calciphylaxis remain unclear, which has led to a lack of well-established therapies for its treatment. During the disease, severe pain is a common feature, often accompanied by tactile hypersensitivity, although the pain intensity may vary. Initial skin manifestations can manifest as induration, plaques, nodules, livedo, or purpura. Patients usually exhibit multiple bilateral lesions, with the surrounding skin developing a leather-like texture. These initial lesions progress rapidly into stellate ulcers with a foul odor and the formation of black eschars. Sepsis resulting from these wounds is the leading cause of deat...

  Calciphylaxis, also known as calcification uremic arteriolopathy, is a rare disease thought to occur due to arteriolar calcifications of the dermis and is responsible for ischemia with cutaneous necrosis and painful panniculitis. Calciphylaxis incidence rate of 3.49 per 1000 patient-years among the patients with end-stage renal disease (ESRD) on chronic hemodialysis. Thelansis’s “Calciphylaxis Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Calciphylaxis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of Calciphylaxis across 8 MM market from the centre of Excellence/ Public/ Private hospitals parti...

  Calciphylaxis, or calcification uremic arteriolopathy, is a rare disease thought to occur due to arteriolar calcifications of the dermis and is responsible for ischemia with cutaneous necrosis and painful panniculitis.   Etiology- The cause of calciphylaxis is not properly understood. The primary event is occlusion of the small blood vessels in the skin by a thrombus (blood clot), which results in spreading ischaemia and skin necrosis. It is thought that the clots occur because of calcification within the walls of the blood vessels.   Epidemiology- Calciphylaxis incidence rate of 3.49 per 1000 patient-years among the patients with end-stage renal disease (ESRD) on chronic hemodialysis.   The competitive landscape of Calciphylaxis includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary. KOLs insights of Calc...